RxDoctor Payments Data

Zachary Lill, MD

Cardiovascular Disease · Orchard Park, NYNPI 1881911519

Payments from drug & device makers

$66,761in general payments, 2019–2025

Across 676 payments — averaging $98.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$20K
  • Pfizer$15K
  • Abbott$14K
  • Medtronic$8K
  • Impulse Dynamics (USA) Inc.$5K
  • Biosense Webster, Inc.$1K
  • plus $5K from 37 others

What the payments were for

  • Consulting fees$9002%
  • Speaking & faculty fees$13,67527%
  • Travel & lodging$6,09212%
  • Food & beverage$29,76459%
  • Education$150%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$66,761 in reported general payments places this provider in the 90th percentile of 2,302 cardiovascular disease providers in New York.

See all cardiovascular disease providers in New York

Medicare billing

Part B allowed, 2024
$94,471
Medicare patients
499
Services billed
1,139

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban165$151,595
MultaqDronedarone Hcl75$70,882
XareltoRivaroxaban17$28,587
Flecainide Acetate247$5,738
Metoprolol Succinate197$2,569
Amiodarone Hcl59$1,340
Diltiazem 24hr Er (Cd)Diltiazem Hcl53$829
Mexiletine Hcl15$597
Cartia XtDiltiazem Hcl18$220
Metoprolol Tartrate22$187
Doxycycline Hyclate11$71

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$14,712$151,595165 claims
Sanofi-aventis U.S. LLCMultaq$246$70,88275 claims
Johnson & JohnsonXarelto$96$28,58717 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,302 cardiovascular disease providers in New York.

Other cardiovascular disease in Orchard Park

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →